AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
|Webcasts|April 26, 2022
Industrializing High-Throughput Glycoproteomics Using AI for Clinical Use
Author(s)Agilent
Aberrant glycosylation of proteins has been implicated in key steps of disease biology, including the hallmarks of cancer as well as inflammation cascades associated with autoimmunity and aging. InterVenn Biosciences harnesses the predictive powers of artificial intelligence combined with cutting edge mass spectrometry to discover clinically relevant biomarkers that can only be revealed by high-resolution analysis of the glycoproteome.
Glycans (carbohydrates) are one of four major classes of biomacromolecules present in all lifeforms. Driven by complex biosynthetic pathways involving genetic and environmental factors, glycans are adaptive to environmental changes. Contrary to other post-translational modifications that typically act as on/off switches, glycosylation dynamically affects protein structure and function. Aberrant glycosylation of proteins has been implicated in key steps of disease biology, including the hallmarks of cancer as well as inflammation cascades associated with autoimmunity and aging. Historically, glycoproteins have been analytically and computationally challenging to study at scale. Unlike DNA, RNA, and proteins, glycans are structurally complex and their synthesis is not template-based. InterVenn has built a platform that overcomes these challenges.
InterVenn Biosciences harnesses the predictive powers of artificial intelligence combined with cutting edge mass spectrometry to discover clinically relevant biomarkers that can only be revealed by high-resolution analysis of the glycoproteome. We have identified distinct glycopeptide signatures at various stages for diseases including cancer, autoimmune and neurodegeneration. The data InterVenn Biosciences produces has the potential for developing various clinical applications such as early diagnosis, companion diagnostics, prognosis, treatment selection, patient enrichment, recurrence monitoring and biomarker discovery.
InterVenn Biosciences glycoproteomics based classifiers show high specificity and sensitivity for indications including Ovarian, CRC, Prostate, Pancreatic, Lung, Liver, Melanoma and many other indications.
Key Learning Objectives:
Mass Spectrometry-based and glycoproteomics clinical application.
Who Should Attend:
To all academicians and industry partners interested to learn more about the real-world clinical application of glycoproteomics on cancer diagnosis.
Speakers
Dr. Low Ley Hian
Director of Development
InterVenn Biosciences
Dr Low obtained his PhD from The Florey Institute of Neuroscience and Mental Health, The University of Melbourne in 2013 and then moved to San Francisco for his postdoctoral fellowship at the University of California San Francisco (UCSF). In 2017, Dr Low cross-path with InterVenn Biosciences and became the founding member of InterVenn Biosciences. With the recent success with InterVenn Series C fundraising led by Softbank, InterVenn Biosciences has expanded to a more than 200 people company and is currently operating in the USA, Malaysia, Philippines and Australia. Currently, Dr Low serves as the Director of Development at InterVenn focusing on developing cancer diagnostic products using glycoproteomics and machine learning technology.
Register Free:
Related to this article
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
4
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
5